- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT07736885
Evaluation of Clinical Efficacy and Mechanism of Hand Jing-Well Acupoint Transcutaneous Electrical Stimulation in Improving Post-Stroke Cognitive Impairment
This study evaluates a non-invasive electrical stimulation therapy applied to specific acupoints on the fingers (called Jing-Well points) to improve thinking and memory problems after stroke.
Purpose: Many stroke survivors develop cognitive difficulties (problems with memory, attention, and decision-making). Current treatments are limited. This study tests whether gentle electrical stimulation to hand acupoints can improve these symptoms.
Who can participate: Adults aged [35-80] who have had an ischemic stroke and now have mild to moderate cognitive impairment.
What happens: Participants will be randomly assigned to receive either (1) active electrical stimulation to hand Jing-Well points, (2) sham (fake) stimulation. Treatment will last 4 weeks, 6 sessions per week, each 30 minutes, with a stimulation frequency of 10 Hz and intensity adjusted to each participant's tolerance. Cognitive tests and brain imaging will be done before and after treatment.
Potential benefits: Participants may experience improved cognitive function. The study will also help researchers understand how this therapy works in the brain.
Risks: The electrical stimulation may cause mild tingling or skin irritation at the electrode sites. Brain imaging is non-invasive and safe. All procedures will be performed by trained professionals.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Liang Gao
- Phone Number: 8618722216295
- Email: Gaoliang202605@163.com
Study Locations
-
-
Tianjin Municipality
-
Tianjin, Tianjin Municipality, China, 300073
- Recruiting
- The First Teaching Hospital of Tianjin University of Traditional Chinese Medicine
-
Contact:
- Liang Gao
- Phone Number: 8618722216295
- Email: Gaoliang202605@163.com
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Aged 35-80 years;
- Stroke duration within 2 weeks to 6 months post-onset;
- Cognitive impairment confirmed by neuropsychological assessment: Montreal Cognitive Assessment (MoCA) score < 26;
- Clinical evaluation excludes delirium, major depressive disorder, schizophrenia, or other primary psychiatric/behavioral disorders as the principal cause of current cognitive impairment. No history of other known neurological diseases that may cause cognitive impairment (e.g., multiple sclerosis, encephalitis, Parkinson's disease, post-traumatic dementia, normal pressure hydrocephalus, etc.);
- No severe aphasia; able to cooperate with scale assessments and complete the treatment protocol required by this study;
- Voluntary participation in this study; the participant or their legally authorized representative has signed the informed consent form.
Exclusion Criteria:
- Unstable vital signs or life-threatening comorbidities;
- Implanted devices (cardiac pacemaker/defibrillator, deep brain stimulator, etc.);
- History of epilepsy or epileptic seizures;
- Pregnant or lactating women;
- Concurrent use of other medications affecting cognitive function;
- Allergy to the study intervention device or history of serious adverse reactions;
- Severe arrhythmia, malignant hypertension, or severe dysfunction of vital organs (heart, liver, kidney, etc.);
- Individuals unable to participate in treatment due to severe hearing or visual impairment, or bilateral limb paralysis.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Active TES Group
Participants receive transcutaneous electrical stimulation at hand Jing-Well acupoints (Shaoze SI1, Shangyang LI1, Zhongchong PC9, Guanchong SJ1, Shaochong HT9, and Dadun LR1) using a portable stimulator.
Stimulation parameters: 10 Hz square wave, pulse width 320 μs, intensity adjusted to individual tolerance (typically 0-1 mA), 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total).
|
Device-based transcutaneous electrical stimulation (TES) delivered to six hand Jing-Well acupoints: Shaoze (SI1), Shangyang (LI1), Zhongchong (PC9), Guanchong (SJ1), Shaochong (HT9), and Dadun (LR1).
A custom-designed portable electrical stimulator (model YM-JX-V01, manufactured by Yimai Artificial Intelligence Medical Technology (Tianjin) Co., Ltd.) is used with disposable self-adhesive reference electrodes (4 × 4 cm) and stimulation electrodes (diameter 5 mm).
Stimulation parameters: square wave, frequency 10 Hz, pulse width 320 μs, intensity individually titrated to sensory threshold (typically 0-1 mA), session duration 30 minutes.
Treatment schedule: 6 sessions per week (Monday-Saturday) for 4 consecutive weeks, totaling 24 sessions.
Electrodes are placed bilaterally at the designated acupoints according to WHO Standard Acupuncture Point Locations.
|
|
Sham Comparator: Sham TES Group
Participants receive sham transcutaneous electrical stimulation at hand Jing-Well acupoint locations using an identical-appearing device with the same electrode placement pattern as the active group.
The device delivers ineffective stimulation (0 Hz, no current output) while maintaining identical visual and tactile feedback.
Sessions follow the same schedule as the active group: 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total).
|
Device-based sham transcutaneous electrical stimulation (TES) delivered to six hand Jing-Well acupoints: Shaoze (SI1), Shangyang (LI1), Zhongchong (PC9), Guanchong (SJ1), Shaochong (HT9), and Dadun (LR1).
A custom-designed portable electrical stimulator with open-circuit design (model YM-JX-V01, manufactured by Yimai Artificial Intelligence Medical Technology (Tianjin) Co., Ltd.) is used with disposable self-adhesive reference electrodes (4 × 4 cm) and stimulation electrodes (diameter 5 mm).
The device delivers ineffective stimulation (0 Hz, no current output) while maintaining identical visual and tactile feedback.
Sessions follow the same schedule as the active group: 30 minutes per session, 6 sessions per week for 4 consecutive weeks (24 sessions total).
Electrodes are placed bilaterally at the designated acupoints according to WHO Standard Acupuncture Point Locations.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
MoCA(Montreal Cognitive Assessment)
Time Frame: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Mini-Mental State Examination(MMSE)
Time Frame: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
Vascular Dementia Assessment Scale-cognitive subscale(VaDAS-cog )
Time Frame: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
Activities of Daily Living Scale(ADL)
Time Frame: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Whole-brain frequency band absolute and relative power derived from resting-state electroencephalography (EEG)
Time Frame: From enrollment to the end of treatment at 4 weeks
|
Resting-state EEG signals will be acquired.
Absolute power and relative power of multiple frequency bands (delta, theta, alpha, beta) across the whole brain will be quantified to reflect cortical electrical activity.
|
From enrollment to the end of treatment at 4 weeks
|
|
Concentration changes of oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (HbR) measured by functional near-infrared spectroscopy (fNIRS)
Time Frame: From enrollment to the end of treatment at 4 weeks
|
Prefrontal cortical hemodynamic signals will be acquired via resting-state functional near-infrared spectroscopy.
Concentration changes of oxygenated hemoglobin (HbO) and deoxygenated hemoglobin (HbR) will be quantified to evaluate cerebral hemodynamic function.
|
From enrollment to the end of treatment at 4 weeks
|
|
C-Reactive Protein
Time Frame: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
|
Folic Acid / Folate
Time Frame: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
|
Homocysteine(Hcy)
Time Frame: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
|
|
Vitamin B12 / Cobalamin
Time Frame: From enrollment to the end of treatment at 4 weeks
|
From enrollment to the end of treatment at 4 weeks
|
Collaborators and Investigators
Publications and helpful links
General Publications
- Easton JD, Saver JL, Albers GW, Alberts MJ, Chaturvedi S, Feldmann E, Hatsukami TS, Higashida RT, Johnston SC, Kidwell CS, Lutsep HL, Miller E, Sacco RL; American Heart Association; American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; Interdisciplinary Council on Peripheral Vascular Disease. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association Stroke Council; Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular Nursing; and the Interdisciplinary Council on Peripheral Vascular Disease. The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists. Stroke. 2009 Jun;40(6):2276-93. doi: 10.1161/STROKEAHA.108.192218. Epub 2009 May 7.
- Sacco RL, Kasner SE, Broderick JP, Caplan LR, Connors JJ, Culebras A, Elkind MS, George MG, Hamdan AD, Higashida RT, Hoh BL, Janis LS, Kase CS, Kleindorfer DO, Lee JM, Moseley ME, Peterson ED, Turan TN, Valderrama AL, Vinters HV; American Heart Association Stroke Council, Council on Cardiovascular Surgery and Anesthesia; Council on Cardiovascular Radiology and Intervention; Council on Cardiovascular and Stroke Nursing; Council on Epidemiology and Prevention; Council on Peripheral Vascular Disease; Council on Nutrition, Physical Activity and Metabolism. An updated definition of stroke for the 21st century: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2013 Jul;44(7):2064-89. doi: 10.1161/STR.0b013e318296aeca. Epub 2013 May 7.
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- TYLL2026-K-076
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.